Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 03, 2026
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time
11:52am, Monday, 17'th Mar 2025
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time
New Data Highlight the Positive Impact of Exact Sciences' Oncotype DX® Test on Patient Care and Healthcare Efficiency
05:00am, Wednesday, 12'th Mar 2025
BAAR, Switzerland--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Onc
3 Top Cancer Biotechs to Keep An Eye On in 2025
09:25am, Friday, 07'th Mar 2025
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
2 Stocks Down 59% and 34% to Buy and Hold
12:00pm, Monday, 24'th Feb 2025
Warren Buffett, arguably the greatest investor of all time, once said it is wise for investors to be fearful when others are greedy. One way to apply this advice from the Oracle of Omaha is to look at
Exact Sciences to Participate in March Investor Conferences
06:00am, Monday, 24'th Feb 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow
Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point
12:16am, Monday, 24'th Feb 2025
Exact Sciences posted strong Q4 revenue growth but faced a significant EPS miss due to an $838M impairment charge from the Thrive acquisition. Despite the negative market reaction, Exact's core busine
EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y
09:10am, Thursday, 20'th Feb 2025
Exact Sciences' fourth-quarter 2024 performance benefits from the robust momentum in Cologuard adoption.
Exact Sciences Corporation (EXAS) Q4 2024 Earnings Call Transcript
08:37pm, Wednesday, 19'th Feb 2025
Exact Sciences Corporation (NASDAQ:EXAS ) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman a
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
06:26pm, Wednesday, 19'th Feb 2025
Exact Sciences (EXAS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.27 per share a year ago.
Exact Sciences Announces Fourth Quarter 2024 Results
04:05pm, Wednesday, 19'th Feb 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $713 million for
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that the U.S. Patent Trial and Appeal Board instituted inter partes review of U.S. Patent No. 11,970,746 owned by Exact Sciences.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Thursday, 13'th Feb 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Wednesday, 12'th Feb 2025
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences Schedules Fourth Quarter 2024 Earnings Call
06:00am, Monday, 03'rd Feb 2025
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Tuesday, 28'th Jan 2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
